This tool helps you understand the potential benefits and risks of menopausal hormone therapy (MHT) based on your personal profile. It is grounded in the most current evidence and professional guidelines.
Whether MHT is right for you depends on several factors: your age, how recently menopause began, your symptoms, your personal and family health history, and the type of therapy considered.
What changed: In November 2025, the FDA removed the black box warnings from estrogen-containing hormone therapy products. After reviewing 20+ years of evidence since the original warnings, the FDA concluded that the risks had been overstated, and that for many women, the benefits of MHT substantially outweigh the risks. New labels will include age-specific guidance emphasizing that initiation within 10 years of menopause is associated with a favorable benefit-risk profile.
What this tool does: It walks you through a few questions about your health, then generates a personalized summary of the potential benefits and risks based on current evidence from The Menopause Society (2022), the International Menopause Society (2024), the FDA (2025), and recent meta-analyses. It gives you the numbers and the questions to bring to your provider.
This is a decision support tool, not a prescription. It does not replace a conversation with your healthcare provider. Hormone therapy decisions should be individualized based on your complete medical history.
Your data stays on your phone. No information is sent to any server. No account is needed. Nothing is stored after you close this page.
This summary is based on the following sources. It intentionally does not rely on the original 2002 WHI findings, which studied women averaging age 63 (more than a decade past menopause) and used a formulation (oral conjugated equine estrogen + medroxyprogesterone acetate) that is no longer the standard of care. Those findings, while important historically, were widely misapplied to younger symptomatic women and led to two decades of undertreated menopause symptoms.
The evidence used here reflects the post-WHI reanalysis data and the current consensus of major professional societies: